The available therapies for anti-myeloperoxidase (MPO) glomerulonephritis (GN) are broadly immunosuppressive and associated with serious adverse effects, particularly infections. A potentially safer approach is to specifically target anti-MPO immunity to restore tolerance to this autoantigen without compromising the immune response to pathogens. Now, Dragana Odobasic and colleagues report that tolerogenic dendritic cells (DCs) induced MPO-specific immunosuppression and attenuated anti-MPO GN in a mouse model.
“We chose to investigate tolerogenic DCs because they have a unique capacity to induce antigen-specific immunosuppression by presenting antigens to T cells, and because phase I trials have proven their feasibility and safety as a potential therapeutic approach in patients with various autoimmune diseases,” explains Odobasic. To generate tolerogenic DCs that specifically inhibit anti-MPO autoimmunity, the researchers cultured DCs with a NF-κB inhibitor to induce an anti-inflammatory phenotype and then exposed them to MPO. “These MPO-loaded tolerogenic DCs can present MPO and thus turn off disease-driving MPO-specific T cells,” says Odobasic.
Injection of the MPO-loaded DCs induced inhibitory IL-10-producing regulatory T cells in MPO-immunized mice and suppressed established anti-MPO autoimmunity, glomerular injury and proteinuria in mice with anti-MPO GN. The DCs did not inhibit immunity against an irrelevant antigen, confirming that their immunosuppressive effects were MPO-specific.
“These studies will pave the way for progress of MPO-presenting tolerogenic DCs into clinical trials,” concludes Odobasic. “By turning off anti-MPO autoimmunity, this therapy comes as close as possible to a cure for anti-MPO GN and has the potential to provide immense benefit to patients by enabling them to avoid complications resulting from the non-antigen-specific effects of current therapies.”
References
Original article
Odobasic, D. et al. Tolerogenic dendritic cells attenuate experimental autoimmune antimyeloperoxidase glomerulonephritis. J. Am. Soc. Nephrol. https://doi.org/10.1681/ASN.2019030236 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carney, E.F. Tolerogenic cell therapy for glomerulonephritis. Nat Rev Nephrol 15, 662 (2019). https://doi.org/10.1038/s41581-019-0206-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-019-0206-8